GLP-1 agonists: a game changer in pain treatment and addiction
- 28 July 2025
- journal article
- review article
- Published by Taylor & Francis in Pain Management
- Vol. 15 (10) , 753-765
Abstract
Chronic pain imposes a significant healthcare burden, with treatments often limited by side effects, opioid dependency, and preventable surgeries. Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1RAs), developed for diabetes and obesity, may offer novel analgesia and treat drug-seeking behavior. This review examines the role of GLP-1RAs in pain management, focusing on inflammation, macrophage repolarization, oxidative stress, and dopaminergic pathways in substance use disorders. We conducted a literature search in PubMed and Embase (Ovid) from January 2000 to February 2025, identifying studies on GLP-1RA and pain in headaches, osteoarthritis, diabetic neuropathy, and substance use disorders. GLP-1RAs offer a promising shift in pain management, potentially reducing opioid dependence, preventing surgical interventions, and lowering healthcare costs. While early evidence suggests analgesic and disease-modifying effects beyond weight loss, significant knowledge gaps remain. In osteoarthritis, they appear to reduce inflammation and cartilage degradation, but trials in non-obese, non-comorbid patients are needed. In diabetic neuropathy, GLP-1RAs show potential for nerve repair, but optimal dosing and long-term efficacy need clarification. Preclinical data support GLP-1RAs signaling in migraines, but human studies are lacking. Trials in alcohol addiction show promise, though evidence for other substances remains inconclusive. Larger-scale trials are needed to confirm these findings.Keywords
This publication has 63 references indexed in Scilit:
- Once-Weekly Semaglutide in Adults With Alcohol Use DisorderJAMA Psychiatry, 2025
- Repurposing Semaglutide and Liraglutide for Alcohol Use DisorderJAMA Psychiatry, 2025
- Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed SemaglutideJAMA Ophthalmology, 2024
- Glucagon-like peptide-1 receptor agonists reverse nerve morphological abnormalities in diabetic peripheral neuropathyDiabetologia, 2024
- Lessons for Better Pain Management in the Future: Learning from the PastPain and Therapy, 2020
- Cue reactivity and its relation to craving and relapse in alcohol dependence: a combined laboratory and field studyPsychopharmacology, 2015
- Osteoarthritis joint pain: The cytokine connectionCytokine, 2014
- Tumor necrosis factor causes persistent sensitization of joint nociceptors to mechanical stimuli in ratsArthritis & Rheumatism, 2010
- Lost Productive Time and Cost Due to Common Pain Conditions in the US WorkforceJAMA, 2003
- Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous systemJournal of Comparative Neurology, 1998